Let the right ones in – boosting immunotherapy for pancreatic cancer

Researchers recently published their results in animal models showing that the addition of certain agents (checkpoint drug -CXCR2-blocker), which promote specific immune cells in the body (T-Cells) to fight cancer, combined with the chemotherapy agents (Gemcitabine), had dramatic effects in treating pancreatic cancer.

Clinical trials in patients with pancreatic cancer are however, required to determine if there are truly beneficial effects.

Realistically it is several years away before we know if such agents dramatically improve outcomes in pancreatic cancer, but the animal studies performed so far are promising.

Review by Dr Mehrdad Nikfarjam

You can read the original article here.